Literature DB >> 12132564

Economic evaluations of olanzapine and risperidone.

James W Shaw1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12132564     DOI: 10.1093/ajhp/59.14.1366

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  2 in total

1.  Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.

Authors:  Valentinas Maciulis; Istvan Bitter; Raimundas Milasiunas; Algirdas Dembinskas; Liaudminas Radavicius; Algirdas Kaunas; Martin Dossenbach; Daniel Walker
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

Review 2.  Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.

Authors:  Hans-Jürgen Möller
Journal:  Drugs       Date:  2007       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.